placeholder image
B. H. Fireman All authors
About
Publications While At 开云体育
selected publications
Journal Article
  • Methods to adjust for confounding in test-negative design COVID-19 effectiveness studies: simulation study. 
    JMIR formative research. 2025
  • 18 Years - VISION and IVY Networks, September 2023-January 2024. 
    MMWR: Morbidity and Mortality Weekly Report. 2024
  • 18 years with immunocompromising conditions - VISION Network, September 2023-February 2024. 
    MMWR: Morbidity and Mortality Weekly Report. 2024
  • Clinical epidemiology and risk factors for critical outcomes among vaccinated and unvaccinated adults hospitalized with COVID-19-VISION Network, 10 states, June 2021-March 2023. 
    Clinical Infectious Diseases. 2024
  • Influenza vaccine effectiveness against influenza A-associated emergency department, urgent care, and hospitalization encounters among US adults, 2022-2023. 
    Journal of Infectious Diseases. 2024
  • Mortality risk after COVID-19 vaccination: a self-controlled case series study. 
    Vaccine. 2024
  • Respiratory syncytial virus (RSV) vaccine effectiveness against RSV-associated hospitalisations and emergency department encounters among adults aged 60 years and older in the USA, October, 2023, to March, 2024: a test-negative design analysis. 
    Lancet (London, England). 2024
  • Tinnitus after COVID-19 vaccination: findings from the vaccine adverse event reporting system and the vaccine safety datalink. 
    American Journal of Otolaryngology. 2024
  • Vaccine effectiveness against pediatric influenza-A-associated urgent care, emergency department, and hospital encounters during the 2022-2023 season: VISION Network. 
    Clinical Infectious Diseases. 2024
  • A broad assessment of COVID-19 vaccine safety using tree-based data-mining in the vaccine safety datalink. 
    Vaccine. 2023
  • A safety study evaluating non-COVID-19 mortality risk following COVID-19 vaccination. 
    Vaccine. 2023
  • Effectiveness of BNT162b2 COVID-19 vaccination in children and adolescents. 
    Pediatrics. 2023
  • Effectiveness of COVID-19 vaccines at preventing emergency department or urgent care encounters and hospitalizations among immunocompromised adults: an observational study of real-world data across 10 US states from August-December 2021. 
    Vaccine. 2023
  • Estimates of bivalent mRNA vaccine durability in preventing COVID-19-associated hospitalization and critical illness among adults with and without immunocompromising conditions - VISION Network, September 2022-April 2023. 
    American Journal of Transplantation. 2023
  • Estimation of COVID-19 mRNA vaccine effectiveness and COVID-19 illness and severity by vaccination status during Omicron BA.4 and BA.5 sublineage periods. 
    JAMA network open. 2023
  • Number needed to vaccinate with a COVID-19 booster to prevent a COVID-19-associated hospitalization during SARS-CoV-2 Omicron BA.1 variant predominance, December 2021-February 2022, VISION Network: a retrospective cohort study. 
    Lancet Reg Health Am. 2023
  • Protection from COVID-19 mRNA vaccination and prior SARS-CoV-2 infection against COVID-19-associated encounters in adults during Delta and Omicron predominance. 
    Journal of Infectious Diseases. 2023
  • Protection of two and three mRNA vaccine doses against severe outcomes among adults hospitalized with COVID-19--VISION Network, August 2021 to March 2022. 
    Journal of Infectious Diseases. 2023
  • Safety signal identification for COVID-19 bivalent booster vaccination using tree-based scan statistics in the Vaccine Safety Datalink. 
    Vaccine. 2023
  • Tree-based data mining for safety assessment of first COVID-19 booster doses in the Vaccine Safety Datalink. 
    Vaccine. 2023
  • Vaccine effectiveness against influenza-associated urgent care, emergency department, and hospital encounters during the 2021-2022 season, VISION Network. 
    Journal of Infectious Diseases. 2023
  • Early estimates of bivalent mRNA vaccine effectiveness in preventing COVID-19-associated emergency department or urgent care encounters and hospitalizations among immunocompetent adults - VISION Network, nine states, September-November 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated - VISION Network, 10 states, December 2021-June 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 Pfizer-BioNTech BNT162b2 mRNA vaccination in preventing COVID-19-associated emergency department and urgent care encounters and hospitalizations among nonimmunocompromised children and adolescents aged 5-17 years - VISION Network, 10 states, April 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of COVID-19 mRNA vaccines against COVID-19-associated hospitalizations among immunocompromised adults during SARS-CoV-2 Omicron predominance - VISION Network, 10 states, December 2021-August 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of a third dose of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during oeriods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of homologous and heterologous COVID-19 booster doses following 1 Ad.26.COV2.S (Janssen (Johnson & Johnson)) vaccine dose against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults - VISION Network, 10 states, December 2021-March 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Effectiveness of two-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults-nine states, January-September 2021. 
    American Journal of Transplantation. 2022
  • Estimation of COVID-19 mRNA vaccine effectiveness against medically attended COVID-19 in pregnancy during periods of Delta and Omicron variant predominance in the United States. 
    JAMA network open. 2022
  • Incidence of Guillain-Barr茅 syndrome after COVID-19 vaccination in the Vaccine Safety Datalink. 
    JAMA network open. 2022
  • Risk of myocarditis and pericarditis following BNT162b2 and mRNA-1273 COVID-19 vaccination. 
    Vaccine. 2022
  • Safety of COVID-19 vaccination in United States children ages 5 to 11 years. 
    Pediatrics. 2022
  • Waning 2-dose and 3-dose effectiveness of mRNA vaccines against COVID-19-associated emergency department and urgent care encounters and hospitalizations among adults during periods of Delta and Omicron variant predominance - VISION Network, 10 states, August 2021-January 2022. 
    MMWR: Morbidity and Mortality Weekly Report. 2022
  • Waning of vaccine effectiveness against moderate and severe covid-19 among adults in the US from the VISION network: test negative, case-control study. 
    BMJ (Clinical research ed.). 2022
  • COVID-19 vaccination coverage among insured persons aged 鈮�16 years, by race/ethnicity and other selected characteristics - eight integrated health care organizations, United States, December 14, 2020-May 15, 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Effectiveness of 2-dose vaccination with mRNA COVID-19 vaccines against COVID-19-associated hospitalizations among immunocompromised adults - nine states, January-September 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Effectiveness of Covid-19 vaccines in ambulatory and inpatient care settings. 
    New England Journal of Medicine. 2021
  • Laboratory-confirmed COVID-19 among adults hospitalized with COVID-19-like illness with infection-induced or mRNA vaccine-induced SARS-CoV-2 immunity - nine states, January-September 2021. 
    MMWR: Morbidity and Mortality Weekly Report. 2021
  • Surveillance for adverse events after COVID-19 mRNA vaccination. 
    JAMA. 2021
  • Safety of measles-containing vaccines in 1-year-old children. 
    Pediatrics. 2015
  • Effect of age on the risk of fever and seizures following immunization with measles-containing vaccines in children. 
    JAMA pediatrics. 2013
  • Guillain-Barre syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009-2011. 
    PloS One. 2013
  • Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes. 
    Diabetes care. 2013
  • Super learning to hedge against incorrect inference from arbitrary parametric assumptions in marginal structural modeling. 
    Journal of Clinical Epidemiology. 2013
  • Dynamic marginal structural modeling to evaluate the comparative effectiveness of more or less aggressive treatment intensification strategies in adults with type 2 diabetes. 
    Pharmacoepidemiology and Drug Safety. 2012
  • Measles-containing vaccines and febrile seizures in children age 4 to 6 years. 
    Pediatrics. 2012
  • Safety of zoster vaccine in adults from a large managed-care cohort: a Vaccine Safety Datalink study. 
    Journal of Internal Medicine. 2012
  • ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. 
    JAMA. 2011
  • H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project. 
    American Journal of Preventive Medicine. 2011
  • Measles-mumps-rubella-varicella combination vaccine and the risk of febrile seizures. 
    Pediatrics. 2010
  • Near real-time surveillance for influenza vaccine safety: proof-of-concept in the Vaccine Safety Datalink Project. 
    American Journal of Epidemiology. 2010
    • Conference Poster
  • Impact of specific glucose-control strategies on microvascular outcomes in 58,000 adults with type 2 diabetes [poster]
    2013
    • presentations
    Contact
    full name
  • B. H. Fireman
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at 开云体育. Publications in prior years appear in grey.
    Collaboration